A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 900 articles on Celgene.
Is Celgene a Buy?

This biotech stock might not be around for much longer. Is it a smart pick to buy now before it's...

3 Top U.S. Stocks to Watch

Big changes are happening at these three U.S. companies, which makes them names worth watching to...



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $89.10
Prev Close: $88.65
Open: $88.92
Bid: $88.95
Ask: $88.96
Day's Range: $88.72 - $89.87
52wk Range: $58.59 - $96.95
Volume: 4,958,916
Avg Vol 9,697,150
Market Cap: $70B
P/E (ttm): 22.50
EPS (ttm): $3.94
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2267 Outperform
78 Underperform
CAPS All Stars
 
471 Outperform
15 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

74% Approve

Based on 86 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers